Notícias

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC

Hims & Hers Health on Wednesday said it will offer five formulations of peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform, all of which are not approved by regulators. Even as it announced the new products, Hims & Hers acknowledged it has more to learn about how best to use the peptides and how effective they are — underscoring the uncertainty surrounding the growing space. The new offerings come after the federal government eased restrictions on compounding certain unapproved peptides, which are short chains of amino ​acids.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.